Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • La Crosse, Wisconsin

Conditions: Coronary Artery Disease
Interventions: Plavix (Clopidogrel); Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 90
States / cities: Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 87 more

Conditions: Venous Thrombosis
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more

Conditions: HIV Infections, Tuberculosis
Interventions: Atazanavir, Rifampin, Ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 3
States / cities: Palo Alto, California • Columbus, Ohio • Nashville, Tennessee

Conditions: Hot Flashes, Memory Loss
Interventions: PhytoSERM tablet, placebo; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 39
States / cities: Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Psychotic Disorders
Interventions: BI 409306, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 16 Years to 30 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Culver City, California • San Diego, California • New Haven, Connecticut + 19 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX); Biological · Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more

Conditions: Leiomyosarcoma, Uterine Neoplasm
Interventions: Letrozole; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C Virus Infection
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 13 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more

Conditions: Dermatomyositis
Interventions: Tofacitinib; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: MD-7246, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 80
States / cities: Huntsville, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 65 more

Conditions: Solid Tumour
Interventions: Capivasertib, Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Aurora, Colorado • Durham, North Carolina • Cleveland, Ohio + 2 more

Conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
Interventions: Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule, Placebo comparator to 20 mg capsule; Drug
Lead sponsor: Institute for Asthma and Allergy; Network
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions: Vaginal estradiol tablets, Vaginal moisturizer; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions: TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more

Conditions: Physical Activity
Interventions: Metformin, Placebo, Carbohydrate Beverage, Protein Beverage; Drug · Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 55 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Benign Prostatic Hyperplasia
Interventions: WC3055, Placebo; Drug · Other
Lead sponsor: Warner Chilcott; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 95
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more

Conditions: Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations, Cancers With TRK Genomic Alterations
Interventions: DCC-2701 tablet; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more

Search by objective public record fields.

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Oral Rivaroxaban in Children With Venous Thrombosis

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

Phytoserms for Menopause Symptoms and Age-Associated Memory Decline

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Study of Tofacitinib in Refractory Dermatomyositis

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

A Study of DCC-2701 in Participants With Advanced Solid Tumors